
AI is about to change healthcare. These 112 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For Brookfield Business, the investment case still rests on buying a complex, value-driven conglomerate at a low sales multiple and trusting management’s capital allocation. The latest results keep that story intact but sharpen the focus. Revenue fell to US$7,168 million and losses remain sizeable, yet the group recycled over US$2 billion of capital, repaid about US$1 billion of debt and put US$700 million into new acquisitions. The ongoing reorganization, aimed at better trading liquidity and a clearer structure, now looks like the key short term catalyst, especially with a refreshed quarterly dividend framework tied to its completion. The flip side is that the business is still unprofitable and reliant on successful deal execution, so any stumble on integration, disposals or the reorganization itself could quickly change sentiment.
However, one risk in particular may matter more than it first appears. Brookfield Business' shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.The Simply Wall St Community’s single fair value estimate clusters around US$0.72, implying a very large gap to the market price. Set that against the current reliance on capital recycling and a still loss making core, and it is clear you are seeing just one lens among many that investors may want to compare.
Explore another fair value estimate on Brookfield Business - why the stock might be worth less than half the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com